HU6

**HU6**
法律規範狀態
法律規範	Investigational;
識別資訊
	IUPAC命名法 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole; ;
CAS號	2231311-68-3
PubChem CID	135205989;
化學資訊
化學式	C11H9N5O7
摩爾質量	323.22 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CN1C(=CN=C1[N+](=O)[O-])COC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-];

HU6是線粒體解偶聯劑2,4-二硝基苯酚(DNP) 的前藥，其旨在最大限度地減慢DNP的吸收速度並削減，以提供更廣泛的治療指數並提高安全性。該藥物由 Rivus Pharmaceuticals 開發，經過測試可減輕代謝功能障礙相關脂肪性肝病並伴危險因素的人群的體重及其肝臟脂肪含量。在 2a 期試驗中，在較高的劑量下，肝臟脂肪平均減少了 30% 以上，並且體重顯著減輕。^[1] ^[2]其2b 期試驗已於 2023 年底啟動。^[3]

參考文獻[編輯]

^ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen. Clinical Trial Landscape in NASH. Clinical Gastroenterology and Hepatology. 2023-07, 21 (8): 2001–2014 [2024-02-23]. doi:10.1016/j.cgh.2023.03.041. （原始內容存檔於2024-04-20）（英語）.
^ Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J. Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet Gastroenterology & Hepatology. 2023-12, 8 (12): 1094–1105 [2024-02-23]. doi:10.1016/S2468-1253(23)00198-X. （原始內容存檔於2024-05-25）（英語）.
^ Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments. Yahoo Finance. 2023-11-15 [2024-02-23]. （原始內容存檔於2023-12-03）（美國英語）.

[1] Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen. Clinical Trial Landscape in NASH. Clinical Gastroenterology and Hepatology. 2023-07, 21 (8): 2001–2014 [2024-02-23]. doi:10.1016/j.cgh.2023.03.041. （原始內容存檔於2024-04-20）（英語）.

[2] Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J. Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet Gastroenterology & Hepatology. 2023-12, 8 (12): 1094–1105 [2024-02-23]. doi:10.1016/S2468-1253(23)00198-X. （原始內容存檔於2024-05-25）（英語）.

[3] Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments. Yahoo Finance. 2023-11-15 [2024-02-23]. （原始內容存檔於2023-12-03）（美國英語）.

[1]

[2]

[3]